Pharmaceuticals firm Strides Arcolab has completed Rs 1,910 crore acquisition of Aspen Pharmacare’s generic pharmaceutical business and related assets in Australia. The transaction has now achieved closure on completion of closing conditions and statutory and regulatory approvals. The acquired business will be integrated and consolidated with Strides effective September 1, 2015.
Earlier in may 2015, Strides Arcolab’s subsidiary Strides Pharma Global Pte, Singapore and Strides (Australia) Pharma Pty, Australia signed definitive agreements with certain wholly owned subsidiaries of Aspen Pharmacare Holdings, a company listed on the Johannesburg Stock Exchange (Aspen), to acquire a generic pharmaceutical business in Australia together with certain branded pharmaceutical assets.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
